SelectQuote (SLQT) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
The 2024 Annual Meeting will be held virtually on November 12, 2024, with voting on director elections, auditor ratification, and executive compensation.
Only stockholders of record as of September 20, 2024, are eligible to vote; 171,464,822 shares outstanding.
Proxy materials, including the annual report, are available online, and voting can be done via internet, phone, mail, or during the meeting.
Voting matters and shareholder proposals
Proposal 1: Elect two Class II directors (Earl H. Devanny III and Raymond F. Weldon) for terms expiring 2027.
Proposal 2: Ratify Deloitte & Touche LLP as independent auditor for fiscal year ending June 30, 2025.
Proposal 3: Approve, by non-binding advisory vote, the compensation of named executive officers (say-on-pay).
Board recommends voting FOR all proposals.
Board of directors and corporate governance
Board consists of seven directors, majority independent, with an average age of 61 and average tenure of nearly eight years.
Board is classified into three classes with staggered three-year terms.
Board leadership is separated between CEO and independent Chairman.
Four standing committees: Audit, Compensation and Talent Development, Nominating and Corporate Governance, and Healthcare Oversight.
Annual board and committee self-evaluations, regular executive sessions, and robust stockholder engagement practices.
Latest events from SelectQuote
- Diversified insurance and healthcare platform achieves strong growth and operational efficiency.SLQT
Investor presentation - Q3 FY2026 revenue up 6% to $430.9M, net income $40.2M, with robust segment growth and outlook.SLQT
Q3 2026 - Revenue up 12% to $537.1M, net income $69.3M, and guidance cut by $40M amid external headwinds.SLQT
Q2 2026 - Board recommends approval of all 2025 meeting proposals, emphasizing performance and governance.SLQT
Proxy Filing - Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.SLQT
Proxy Filing - All proposals passed, including director elections and auditor ratification, with no shareholder questions.SLQT
AGM 2025 - FY2024 results surpassed expectations, with robust growth in revenue and profitability.SLQT
Q4 2024 - Revenue up 26% with strong pharmacy growth; $100M securitization boosts capital flexibility.SLQT
Q1 2025 - Q2 revenue up 19% to $481.1M, net income $53.2M, $350M equity investment secured.SLQT
Q2 2025